Data from 106 AML cases in GEPIA (p = 0.019) and 132 cases in TCGA (p < 0.01) showed that AML patients with high SFXN3 expression had significantly shorter OS than those of patients with low SFXN3 (Figs. 1b and c). Here, SFXN3 is linked to acute myeloid leukemia.